AvenCell Doses First Patient with CRISPR-Engineered Allogeneic Dual-Target CAR-T Therapy AVC-203

April 13, 2026-

AvenCell Therapeutics has announced the first patient dosing in its Phase I QUADvance clinical trial evaluating AVC-203, a CRISPR-engineered allogeneic CAR-T therapy designed for relapsed or refractory B-cell malignancies. The milestone marks the clinical entry of what the company describes as the first dual-targeting CD19/CD20 switchable CAR-T therapy developed using an allogeneic platform.

AVC-203 is engineered to simultaneously target CD19 and CD20, two antigens broadly expressed across B-cell malignancies, including diffuse large B-cell lymphoma. By combining dual-antigen targeting with a proprietary switchable receptor platform, the therapy is designed to enhance tumor coverage while enabling future flexibility to redirect targeting through bridging proteins. This modular approach may allow expansion beyond initial indications without redesigning the core CAR construct.

The therapy is built using CRISPR/Cas9 gene editing to generate an allogeneic, or “off-the-shelf,” CAR-T product derived from healthy donor cells. This strategy aims to address key limitations of autologous CAR-T therapies, including manufacturing delays, variability in T-cell quality, and high costs. In addition, gene editing is used to reduce risks such as graft-versus-host disease and immune rejection, improving the feasibility of broader clinical application.

The ongoing QUADvance study is a Phase I/II trial designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of AVC-203 in adult patients with relapsed or refractory B-cell malignancies. The study is being conducted across multiple sites in the United States and Europe, with plans to expand into Asia. Dose escalation will be followed by dose expansion and a potential pivotal Phase II component.

The clinical advancement of AVC-203 is supported by a grant of up to $40 million from the Japan Agency for Medical Research and Development, reflecting growing global interest in scalable allogeneic cell therapy platforms. Regulatory momentum has also been established, with both IND clearance from the U.S. Food and Drug Administration and clinical trial authorization in Europe.

B-cell malignancies remain a major category of hematologic cancers, and while autologous CAR-T therapies have demonstrated significant efficacy, access and scalability challenges persist. Allogeneic approaches such as AVC-203 aim to overcome these barriers by enabling rapid treatment availability and more consistent manufacturing, potentially expanding access to advanced cellular therapies.